| dc.creator | Befani C., Liakos P. | en |
| dc.date.accessioned | 2023-01-31T07:37:08Z | |
| dc.date.available | 2023-01-31T07:37:08Z | |
| dc.date.issued | 2018 | |
| dc.identifier | 10.1002/jcp.26805 | |
| dc.identifier.issn | 00219541 | |
| dc.identifier.uri | http://hdl.handle.net/11615/71292 | |
| dc.description.abstract | Angiogenesis is a key enabling feature of mammalian embryonic development and tumor progression, which provides oxygen and nutrients that are required for vessel growth and tumor cell growth, respectively. Hypoxia is a driver of this phenomenon and is considered to be one of the most potent initiators of angiogenesis both in vitro and in vivo through stabilization of the transcription factors, hypoxia-inducible factor-1 and -2 (HIF-1 and HIF-2). Although these proteins are highly homologous, emerging evidence suggests that they have unique transcriptional targets and differential impact on angiogenesis. Although HIF-1α is the best known and widely described isoform, recent studies suggest that HIF-2α is a critical regulator of physiological and pathophysiological angiogenesis and, at least, the similiarly important as HIF-1α. Indeed, HIF-2α has been shown to regulate multiple aspects of angiogenesis, including cell proliferation, migration, maturation of blood vessels, and metastasis. In this review, we focus on recent insights into HIF-2α expression, activation, and function under hypoxic and nonhypoxic conditions. We also summarize the current knowledge on the crosstalk between HIF-2 and angiogenesis, describing reported phenotypical changes of HIF-2α genetic models and HIF-2 target genes implicated in angiogenesis. Finally, we provide a survey of recent pharmacologic strategies to specifically target HIF-2 activity. © 2018 Wiley Periodicals, Inc. | en |
| dc.language.iso | en | en |
| dc.source | Journal of Cellular Physiology | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050483500&doi=10.1002%2fjcp.26805&partnerID=40&md5=90dba0bdd03f2b04b364d6ac5a7612a3 | |
| dc.subject | hypoxia inducible factor 2alpha | en |
| dc.subject | oxygen | en |
| dc.subject | basic helix loop helix transcription factor | en |
| dc.subject | endothelial PAS domain-containing protein 1 | en |
| dc.subject | HIF1A protein, human | en |
| dc.subject | hypoxia inducible factor 1alpha | en |
| dc.subject | angiogenesis | en |
| dc.subject | gene expression | en |
| dc.subject | gene targeting | en |
| dc.subject | genetic model | en |
| dc.subject | human | en |
| dc.subject | nonhuman | en |
| dc.subject | priority journal | en |
| dc.subject | protein function | en |
| dc.subject | protein structure | en |
| dc.subject | Review | en |
| dc.subject | angiogenesis | en |
| dc.subject | cell hypoxia | en |
| dc.subject | cell proliferation | en |
| dc.subject | embryo development | en |
| dc.subject | genetics | en |
| dc.subject | mammalian embryo | en |
| dc.subject | metabolism | en |
| dc.subject | neoplasm | en |
| dc.subject | neovascularization (pathology) | en |
| dc.subject | pathology | en |
| dc.subject | physiology | en |
| dc.subject | Basic Helix-Loop-Helix Transcription Factors | en |
| dc.subject | Cell Hypoxia | en |
| dc.subject | Cell Proliferation | en |
| dc.subject | Embryo, Mammalian | en |
| dc.subject | Embryonic Development | en |
| dc.subject | Humans | en |
| dc.subject | Hypoxia-Inducible Factor 1, alpha Subunit | en |
| dc.subject | Neoplasms | en |
| dc.subject | Neovascularization, Pathologic | en |
| dc.subject | Neovascularization, Physiologic | en |
| dc.subject | Oxygen | en |
| dc.subject | Wiley-Liss Inc. | en |
| dc.title | The role of hypoxia-inducible factor-2 alpha in angiogenesis | en |
| dc.type | other | en |